Oviva
Buying intent
26 tracked signals | Top 15 topics are below | Marketing and Engineering are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Oviva's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
10d ago
24d ago
24d ago
16d ago
24d ago
10d ago
16d ago
26d ago
10d ago
26d ago
18d ago
12d ago
24d ago
27d ago
18d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Oviva
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
Primary products / business lines
LinkedIn company profileWe are creating a healthier future for people living with weight-related conditions by offering highly accessible & effective technology-enabled therapy. Oviva works directly with statutory health insurers, doctors and national healthcare systems in the UK, DE & CH and has treated over one million patients.
New capability sought
Employee posts (LinkedIn)Weight Management
Top accounts researching Oviva
names withheld on the public pageThese are companies whose own people brought up Oviva unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
151,426 companies · 839,012 people are researching Artificial Intelligence
Oviva's own team shows 4 signals on this topic. No one outside Oviva has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Mental Health13,563 cos · 51,459 people
- Weight Management289 cos · 1,038 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Leadership — 1 person; Engineering — 1 person; Marketing — 1 person
What's been said
public posts mentioning OvivaUp to 9 public excerpts naming Oviva from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
Hypertension isn't just the world's most common chronic disease. It's the leading risk factor for premature death and in Germany alone, it combines with obesity to drive over €100 billion in annual healthcare and productivity costs. At the same time, there is a real treatment gap: nearly 1 in 3 adults in Europe live with high blood pressure, and half of those diagnosed remain uncontrolled, despite available pharmacotherapy. The missing layer is structured lifestyle support, and it's the layer most healthcare systems struggle to deliver at scale. For World Hypertension Day, our mission at Oviva is to close this gap. In our new German GP survey, 3 in 4 doctors confirmed what we've seen for years: there is a (very) large need for additional lifestyle support for hypertension patients. That's exactly what we built. Oviva Direkt Bluthochdruck, the first dual-effect digital therapeutic reimbursed by Germany's statutory health system, delivered -11 mmHg systolic BP and -4% body weight after 3 months in the randomised HYPE trial. The same therapy that lowers blood pressure also addresses obesity, the most common comorbidity. Real savings for payers. Real productivity gains for the economy.
May 2026More than 20 million Germans live with hypertension. ~7 million of them also live with obesity. And half of all diagnosed patients remain uncontrolled despite available medication. Two of the costliest chronic diseases in our healthcare system, sharing the same patients, yet still treated in silos. As we mark World Hypertension Day, our mission at Oviva is clear: integrating structured lifestyle intervention into the standard hypertension pathway. In our new survey of 400 German practising physicians, 3 in 4 confirmed a (very) large need for exactly this kind of support. We have the evidence. With Oviva Direkt Bluthochdruck, Germany's first dual-effect Digital Therapeutic (DiGA), reimbursed by all statutory health insurers - the randomised HYPE trial showed -11 mmHg systolic BP and -4.14% body weight after 3 months. One therapy, two of Germany's biggest cost drivers addressed. Let's make this the standard, not the exception.
May 2026Half of all patients diagnosed with high blood pressure are still not at target, even with medication. For World Hypertension Day, that gap is what drives our mission at Oviva . Behind every uncontrolled reading is a person at higher risk of stroke, heart attack, and kidney disease and a system carrying the cost of preventable complications. Hypertension is the leading risk factor for premature death globally, yet structured lifestyle support is still missing from most care pathways. The doctors agree. In our new German GP survey, 3 in 4 confirmed a (very) large need for additional lifestyle support for their hypertension patients. This is where digital therapy changes the picture. In Germany, we've launched Oviva Direkt Bluthochdruck earlier this year, tthe first dual-effect Digital Therapeutic, validated in the randomised HYPE trial: -11 mmHg systolic BP & -4.14% body weight after 3 months. The same model can scale across Europe. High-quality, integrated care shouldn't be a luxury. It must become the standard for everyone.
May 2026💫 What a week. At the European Congress on Obesity in Istanbul, I presented our team's findings from 1,270 patients on the Oviva digital UK Tier-3 programme: fewer sick days, reduced healthcare resource use, real outcomes beyond the scale. The findings ran in seven major UK national outlets, including The Times (front page), The Guardian and The Telegraph, and were discussed on today’s Good Morning Britain. 📈 What it shows is something we've been arguing for a long time: effective obesity care doesn't just help individuals. It eases pressure on overstretched health systems and on the economy. That case used to be a hard sell. The data is doing the talking now. 🤝 Huge thanks to Dagmara Wozniak, PhD, MBA, Dr. Felix Schirmann and Yannick Schindler for the work behind this, and to the wider Oviva team in Istanbul this week. Full Times article in the comments ⤵️
May 2026Back to Oviva’s Swiss roots 🇨🇭 Today I had the pleasure of joining the business lunch of the Swiss ambassador Livia Leu here in Berlin together with other startup and scale up companies. Germany remains the 🥇market for Swiss companies to expand to. This was also the case for Oviva several years ago. From the conversations over lunch I took away: * AI remains the hot topics and I feel we are doing well at Oviva of integrating it (newly founded companies that go AI-first are big source of inspiration for us) * Berlin is still a great place for growing companies in Europe and Germany. Despite some voices in the room debating the heydays are over (as having growing up as a teenager in Berlin in the 90s I have a different perspective) * Germans (and maybe Swiss people as well?) always like to complain and rarely call out the good things the government or regulators have done for them. A bit more balanced approach would do well. Thank you Die Botschaft der Schweiz in Deutschland for the invitation. I am looking forward to the next time.
May 2026